Recent Updates
Recently added Catalysts
ARQT Positive Sentiment

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

Key Takeaway: Arcutis Biotherapeutics, Inc. will present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. The presentation will include a fireside chat on April 14 at 11:00 am ET. The company aims to address the needs of patients with immune-mediated dermatological diseases through innovative therapies.
Price reaction · baseline $23.56 (2026-03-31 close) · hit pre-market · 1 other ARQT headline(s) in the window, move may be shared
day 0 close · peak
+2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Arcutis will present at a significant healthcare conference.
  • The company has a growing portfolio of advanced targeted topicals.
  • Arcutis is focused on addressing urgent needs in dermatology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
7.6%
average across 14 past catalysts
Lead asset
ARQ-151- 0.3%
Phase 1 · Plaque Psoriasis

Full Press Release Details

WESTLAKE VILLAGE, Calif., March 31, 2026(GLOBE NEWSWIRE)--Arcutis Biotherapeutics, Inc.(Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the 25thAnnual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.

Details for the Company’s participation are as follows:Fireside Chat:Tuesday, April 14, 2026 at 11:00 am ET

The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visitwww.arcutis.comor follow Arcutis onLinkedIn,Facebook,Instagram, andX.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on The Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

MediaAmanda Sheldon, Head of Corporate Communicationsmedia@arcutis.com

InvestorsBrian Schoelkopf, Head of Investor Relationsir@arcutis.com

Frequently Asked Questions

When will Arcutis present at the Needham Conference?

Arcutis will present at the conference on April 14, 2026.

How can I access the conference webcast?

The webcast can be accessed via the 'Events' section of Arcutis' website.

What is the focus of Arcutis Biotherapeutics?

Arcutis focuses on developing innovations for immune-mediated dermatological diseases.

How long will the webcast replay be available?

The replay of the webcast will be available for 180 days after the conference.

Last updated: Apr 1, 2026